乳腺浸润性导管癌组织中EpCAM、Vimentin、N-Cadherin的表达观察

目的观察乳腺浸润性导管癌组织中上皮细胞黏附分子(Ep CAM)、波形蛋白(Vimentin)、N-钙黏附蛋白(N-Cadherin)的表达变化,并探讨其意义。方法 835例份乳腺浸润性导管癌组织(观察组),其中腺腔A型229例份(A组)、腺腔B型[人类表皮生长因子受体2(HER2)阴性]263例份(B组)、腺腔B型(HER2阳性)92例份(C组)、HER2过表达型90例份(D组)、三阴型161例份(E组),另取60例份乳腺良性病变组织作对照(对照组),检测各组Ep CAM、Vimentin、N-Cadherin,并分析三者表达与乳腺浸润性导管癌临床病理参数的关系。结果观察组中Ep CAM、Vi...

Full description

Saved in:
Bibliographic Details
Published in山东医药 Vol. 56; no. 3; pp. 1 - 4
Main Author 付丽梅 杨名辉 付明霞 李新军
Format Magazine Article
LanguageChinese
Published 滨州市人民医院,山东滨州,256601 2016
Subjects
Online AccessGet full text
ISSN1002-266X
DOI10.3969/j.issn.1002-266X.2016.03.001

Cover

More Information
Summary:目的观察乳腺浸润性导管癌组织中上皮细胞黏附分子(Ep CAM)、波形蛋白(Vimentin)、N-钙黏附蛋白(N-Cadherin)的表达变化,并探讨其意义。方法 835例份乳腺浸润性导管癌组织(观察组),其中腺腔A型229例份(A组)、腺腔B型[人类表皮生长因子受体2(HER2)阴性]263例份(B组)、腺腔B型(HER2阳性)92例份(C组)、HER2过表达型90例份(D组)、三阴型161例份(E组),另取60例份乳腺良性病变组织作对照(对照组),检测各组Ep CAM、Vimentin、N-Cadherin,并分析三者表达与乳腺浸润性导管癌临床病理参数的关系。结果观察组中Ep CAM、Vimentin、N-Cadherin阳性率分别为53.4%、11.4%、9.7%,对照组分别为11.7%、0、0,两组比较,P均〈0.05;A、B、C、D、E组Ep CAM阳性率两两比较(除D组分别与B、E组比较外),A组Vimentin阳性率分别与B、C、D、E组比较,B组Vimentin阳性率分别与E组比较,E组N-Cadherin阳性率与A、B组比较,B组N-Cadherin阳性率分别与C、D组比较,P均〈0.05。Ep CAM、Vimentin、N-Cadherin表达均与乳腺浸润性导管癌肿瘤直径、淋巴结转移、组织学分级、ER、PR、临床分期有关,而且Ep CAM与HER2有关(P均〈0.05)。观察组中Ep CAM与Vimentin、N-Cadherin表达呈正相关(r=0.214、0.136,P均〈0.05),A、C、E组中Ep CAM与Vimentin表达呈正相关(r=0.301、0.290、0.270,P均〈0.05),C、E组中Ep CAM与N-Cadherin表达呈正相关(r=0.003、0049,P均〈0.05)。结论乳腺浸润性导管癌组织中Ep CAM、Vimentin、N-Cadherin表达升高,尤其在三阴型中呈高表达,其可能参与该型乳腺浸润性导管癌的发展、转移过程。
Bibliography:37-1156/R
breast neoplasm; breast carcinoma; epithelial cell adhesion molecule; vimentin; N-cadherin
FU Limei, YANG Minghui, FU Mingxia, LI Xinjun ( Binzhou People's Hospital, Binzhou 256601, China)
Objective To observe the expression change~ of vimentin, N-cadherin, epithelial cell adhesion molecule (EpCAM) in breast infiltrating ductal carcinoma, and to investigate their clinical significance. Methods Totally 835 ca- ses of breast infiltrating ductal carcinoma tissues (observation group) were divided into 229 cases of luminal A (group A), 263 cases of luminal B [ hman epidermal growth factor receptor-2 (HER2) - ] ( group B), 92 cases of luminal B ( HER2 + ) (group C), 90 cases of HER-2 with overexpression (group D) and 161 cases of triple-negative subtype (group E). Meanwhile, another 60 cases of benign breast lesions (control group) were also studied. The expression of EpCAM, vim- entin and N-cadherin was detected in the observation group and the control group, and their relationships with the clinical- patho
ISSN:1002-266X
DOI:10.3969/j.issn.1002-266X.2016.03.001